94E Stock Chart & Stats
€5.05
€0.16(3.46%)
At close: 4:00 PM EDT
€5.05
€0.16(3.46%)
Day’s Range― - ―
52-Week Range€2.72 - €6.00
Previous CloseN/A
Volume151.00
Average Volume (3M)11.00
Market Cap
€354.71M
Enterprise Value€543.01
Total Cash (Recent Filing)€205.13M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta1.34
Next Earnings
Nov 18, 2026EPS Estimate
-0.18Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.13
Shares Outstanding95,829,140
10 Day Avg. Volume0
30 Day Avg. Volume11
Financial Highlights & Ratios
PEG Ratio-0.06
Price to Book (P/B)4.86
Price to Sales (P/S)0.00
P/FCF Ratio-7.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€20.01Price Target Upside296.23% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)-0.73
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance SheetZero reported debt reduces interest burden and near-term solvency pressure while the increase in equity and assets indicates stronger capitalization. This gives Zura greater flexibility to fund clinical development and absorb setbacks without immediate debt-related constraints.
Phase 2 Execution And Indication ExpansionCompleting both Phase 2 enrollment programs above initial targets demonstrates clinical execution and advances important value-creation milestones. Supportive FDA feedback for PMR also broadens tibulizumab’s potential indications, increasing the pipeline’s strategic opportunity.
Extended Clinical Funding RunwayA stated cash runway through at least 2028 provides visibility across planned multi-indication development and reduces the likelihood of near-term financing disruption. This supports continued execution toward Phase 2 readouts while giving management time to evaluate clinical results.
Bears Say
No Commercial RevenueThe absence of revenue means Zura currently lacks an operating income stream to offset research and development costs. Its financial profile therefore depends on external capital and clinical progress, leaving future value highly contingent on successful product development.
Widening Net LossesExpanding losses indicate that operating spending is rising faster than any offsetting income, consistent with an increasingly costly development stage. Persistent deterioration can erode the capital base over time and increase the amount of funding required before commercialization.
Accelerating Cash BurnThe worsening operating and free cash outflows show that clinical advancement is consuming substantial cash without a revenue base to replenish it. Even with current liquidity, sustained burn raises longer-term financing and potential dilution risk if development timelines extend.
Zura Bio News
94E FAQ
What was Zura Bio’s price range in the past 12 months?
Zura Bio lowest stock price was €2.72 and its highest was €6.00 in the past 12 months.
What is Zura Bio’s market cap?
Zura Bio’s market cap is €354.71M.
When is Zura Bio’s upcoming earnings report date?
Zura Bio’s upcoming earnings report date is Nov 18, 2026 which is in 47 days.
How were Zura Bio’s earnings last quarter?
Zura Bio released its earnings results on Aug 11, 2026. The company reported -€0.185 earnings per share for the quarter, missing the consensus estimate of -€0.169 by -€0.017.
Is Zura Bio overvalued?
According to Wall Street analysts Zura Bio’s price is currently Undervalued.
Does Zura Bio pay dividends?
Zura Bio does not currently pay dividends.
What is Zura Bio’s EPS estimate?
Zura Bio’s EPS estimate is -0.18.
How many shares outstanding does Zura Bio have?
Zura Bio has 95,829,140 shares outstanding.
What happened to Zura Bio’s price movement after its last earnings report?
Zura Bio reported an EPS of -€0.185 in its last earnings report, missing expectations of -€0.169. Following the earnings report the stock price went down -6.408%.
Which hedge fund is a major shareholder of Zura Bio?
Currently, no hedge funds are holding shares in DE:94E
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Zura Bio Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€20.01 (296.23% Upside)
€20.01 (296.23% Upside)
Blogger Sentiment
Bullish
DE:94E Sentiment 100%
Sector Average 65%
Sector Average 65%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
2.47%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
35.23%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Zura Bio
Zura Bio Limited is a clinical-stage biotechnology company headquartered in San Diego, California, dedicated to pioneering new therapeutic solutions for immune system and inflammatory diseases. Its key product candidates include ZB-168, an anti-IL7Rα inhibitor engineered to address conditions influenced by the IL7 and TSLP biological pathways. The company is also advancing Torudokimab, a monoclonal antibody that neutralizes IL-33, which is currently in Phase 2 clinical development.
94E Stock 12 Month Forecast
Average Price Target
€20.01
▲(296.23% Upside)